Screener
Krystal Biotech, Inc. KRYS Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands, except per share data) | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Interest and other income, net | 7,753 | 7,345 |
| Income before income taxes | 61,442 | 43,597 |
| Income tax expense | (5,510) | (7,864) |
| Net income | 55,932 | 35,733 |
| Unrealized (loss) gain on available-for-sale securities | (1,577) | 344 |
| Foreign currency translation | (1,182) | 236 |
| Comprehensive income | $53,173 | $36,313 |
| Net income per common share: |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s net income?
- Krystal Biotech, Inc. (KRYS) reported net income of $55.93M in Q1 2026.
- How has Krystal Biotech, Inc.'s net income changed year-over-year?
- Krystal Biotech, Inc.'s net income increased by 56.5% year-over-year, from $35.73M to $55.93M.
- What is the long-term trend for Krystal Biotech, Inc.'s net income?
- Over 4 years (2021 to 2025), Krystal Biotech, Inc.'s net income has grown at a 31.0% compound annual growth rate (CAGR), from -$69.57M to $204.83M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Krystal Biotech, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude